OTCMKTS:IMNPQ Immune Pharmaceuticals (IMNPQ) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free IMNPQ Stock Alerts $0.0010 0.00 (0.00%) (As of 08/17/2022) Add Compare Share Share Today's Range$0.0010▼$0.001050-Day Range N/A52-Week Range$0.0001▼$0.0070VolumeN/AAverage Volume39,081 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Immune Pharmaceuticals alerts: Email Address Ad Prosper Trading AcademyBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)Click Here To Read More About This Game Changing AI Tool About Immune Pharmaceuticals Stock (OTCMKTS:IMNPQ)Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.Read More IMNPQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMNPQ Stock News HeadlinesApril 11, 2024 | msn.comThese Stocks Are Moving the Most Today: Alpine Immune, Vertex, Robinhood, Regeneron, Costco, Constellation Brands, CarMax, and MoreApril 10, 2024 | money.usnews.comVertex Pharmaceuticals to Buy Alpine Immune Sciences for $4.9 BillionApril 10, 2024 | marketwatch.comAlpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.April 10, 2024 | msn.comVertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune dealFebruary 5, 2024 | reuters.comJ&J's immune disorder drug succeeds in studiesDecember 20, 2023 | seekingalpha.comAC Immune: Initial AD Findings Bring About Two Upcoming CatalystsDecember 20, 2023 | forbes.comBest Vitamins And Foods To Boost Your Immune SystemDecember 15, 2023 | markets.businessinsider.comAC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b TrialAugust 21, 2023 | msn.comRegeneron’s Veopoz scores FDA approval for rare immune diseaseAugust 21, 2023 | msn.comFDA Approves Regeneron's Drug For Ultra Rare Immune DisorderAugust 18, 2023 | seekingalpha.comRegeneron wins approval for rare immune disease therapy pozelimabJuly 28, 2023 | benzinga.comNatural Immune Booster Market to Reach $19.67 Billion by 2030, Says Coherent Market Insights (CMI)April 22, 2023 | marketwatch.comImmune Check Point Inhibitor Market Size, Latest Trends, Key Players, Revenue, Report, And Forecast 2031March 28, 2023 | marketwatch.comHuman Immune Health Supplements Market Size and New Revenue Techniques By 2031March 24, 2023 | marketwatch.comNatural Immune Booster Market Top Players By 2031March 6, 2023 | usnews.comJudge: Oxford Schools, Staff Immune From Shooting LawsuitsMarch 1, 2023 | benzinga.comImmune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and DirectionFebruary 28, 2023 | marketwatch.comGlobal Natural Immune Booster Market Report Historical, Current, and Projected Size, in terms of value 2030 By VMReportsJanuary 14, 2023 | foxnews.comChelsea Handler declares she's immune to cancel culture because she's not ‘racist,’ ‘sexist’ ‘idiot’January 14, 2023 | cnn.comStudy shows convalescent plasma works for immune-compromised Covid-19 patients, but it can be hard to findOctober 27, 2022 | theguardian.comImmune system-evading hybrid virus observed for first timeOctober 26, 2022 | reuters.comFor those with HIV or weak immune systems, monkeypox can be fatal -U.S. studyOctober 25, 2022 | yahoo.comTargeting One Type of Immune Cell With Another Slows Cancer Growth in Preclinical StudiesSeptember 12, 2022 | markets.businessinsider.comPositive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJMSeptember 7, 2022 | bizjournals.comCour Pharmaceuticals secures funding to transform the way allergies and autoimmune disorders are treatedSee More Headlines Receive IMNPQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:IMNPQ CUSIPN/A CIK1208261 Webwww.immunepharma.com Phone(201) 464-2677Fax917-398-1915Employees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. John P. Clark (Age 51)Controller & Principal Accounting Officer Comp: $175kMr. Gary H. Rabin (Age 57)Interim CEO & Director Mr. Christine J. PetragliaDirector of Investor RelationsDr. Miri Ben-AmiPres of Immune Oncology Pharmaceuticals IncDr. Boris ShorExec. Director of R&D & Scientific PartnershipsMr. Ranch C. KimballStrategic AdvisorMore ExecutivesKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors IMNPQ Stock Analysis - Frequently Asked Questions How have IMNPQ shares performed in 2024? Immune Pharmaceuticals' stock was trading at $0.0010 at the beginning of the year. Since then, IMNPQ shares have increased by 0.0% and is now trading at $0.0010. View the best growth stocks for 2024 here. How do I buy shares of Immune Pharmaceuticals? Shares of IMNPQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IMNPQ) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immune Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.